Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion, with European Commission (EC) decision anticipated by June 1, 2026 If approved, this would expand the indication of ...

Please provide your email address to receive an email when new articles are posted on . Lomitapide was approved for treatment of homozygous familial hypercholesterolemia in children as young as 2 ...

In briefing documents ahead of an advisory committee meeting on October 17, an FDA panel stated, "In considering a risk management program for lomitapide, FDA must keep in mind that the HoFH patient ...

Homozygous familial hypercholesterolemia is a rare genetic condition that is often characterized by an increased risk of premature cardiovascular (CV) events and cardiac death. Lomitapide decreases ...

Are you taking Lomitapide? Are you aware of the dangers of combining Lomitapide with certain foods, herbs, or alcohol? Drug-food-interactions are seldom discussed but can lead to undesirable side ...

Review the side-effects of Lomitapide as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Lomitapide (trade name: Lojuxta) has been available since July 2013 as additional treatment for adults with homozygous familial hypercholesterolaemia in whom diet and other drugs do not sufficiently ...

FDA reviewers have raised no new concerns about lomitapide ahead of a Wednesday meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. The FDA today released briefing documents that ...

Please provide your email address to receive an email when new articles are posted on . Patients with adult homozygous familial hypercholesterolemia responded favorably to lomitapide when administered ...

Cambridge, MA - Aegerion Pharmaceuticals says it is preparing regulatory filings in the US and Europe for its "orphan" drug lomitapide, a small-molecule microsomal triglyceride transfer protein ...